FertilAI, a fertility technology company developing AI-powered clinical decision support tools, has raised $4.5 million in seed funding. The round was co-led by Longevity Venture Partners and Redseed, with participation from angel investors.
The Israeli company’s Fertilane platform integrates with clinic electronic medical records (EMRs) to optimize fertility treatments through AI-driven insights. The technology supports various aspects of the fertility journey, from determining optimal embryo transfer timing to ovulation tracking and intrauterine insemination (IUI) planning.
The platform has gained significant traction in the market, currently being used by more than 50 physicians across 20,000+ patients globally in 2024. By providing physicians with a unified platform for patient management, treatment plans, and clinic-doctor-patient communications, FertilAI aims to improve both clinical workflow efficiency and treatment outcomes.
“The fertility market is growing at an unprecedented rate and becoming a pressing issue on a global scale,” said Raissa Hacohen, Managing Partner of Longevity Venture Partners. “We invested in FertilAI because the team’s expertise is uniquely suited to solve this market need and its platform has already demonstrated significant traction in the market.”
A key component of the platform is its mobile patient app, which facilitates improved communication between clinics and patients throughout their fertility journey. This comprehensive approach aims to make fertility treatments more accessible and effective.
“Everything we do is focused on providing the opportunity to create families more quickly and affordably,” stated Rohi Hourvitz, CEO of FertilAI. “We want patients to achieve pregnancy much earlier in the process, instead of struggling through multiple rounds of treatment at thousands of dollars each.”
The new funding will support market expansion, hiring, and R&D efforts as the company continues to develop solutions for improved patient care throughout the fertility journey.
